News / 23 October 2026
FDA issues final guidance on apps and software used with prescription drugs
The Food and Drug Administration (FDA) has released final guidance setting out a framework for how drug companies can develop, distribute and label apps used alongside their prescription medicines.[1] It gives recommendations on when app content is subject to FDA submission requirements, when an app should be mentioned on a drug's official label, and what companies should submit to the agency.[1]
The guidance addresses three key questions for industry: when app content is treated as FDA-required labeling versus promotional labeling, when an app should be referenced in a drug's official prescribing information, and what companies should submit to FDA when they distribute app content to users.[1]
The guidance identifies two categories of companion software.[1] Apps connected to a medical device, such as an app paired with an asthma inhaler, generally should be described on the drug's official prescribing label, given the central role the software plays in how the medicine is used.[1]
Standalone apps, such as symptom trackers, dose reminders or health coaching tools, should appear on the prescribing label if the company can show the app is essential for safe and effective use or can demonstrate a meaningful clinical benefit.[1] In most cases, content a companion app displays to users will be treated as promotional material, consistent with how the FDA handles other drug advertising.[1]
Michael Davis, Director of the FDA's Center for Drug Evaluation and Research, said the guidance reflects a commitment to responsible, risk-proportionate oversight of digital health, and that aligning the approach across drug and device centers gives developers a clear and consistent pathway.[1] Jared Seehafer, FDA Deputy Commissioner for Technology, said finalising the guidance gives drug companies and their technology partners a stable foundation to build on.[1]
Background
The FDA says the guidance reflects its ongoing commitment to modernising its regulatory framework to keep pace with rapidly evolving digital health technologies.[1] By giving recommendations for both drug-connected software and standalone software, the agency aims to reduce unnecessary uncertainty for developers and manufacturers while preserving the safety and effectiveness standards that patients and healthcare providers rely on.[1]
This article summarises an official publication for learning purposes. It is not investment advice and makes no forecast of prices or outcomes. Read the original source before relying on any detail.
Sources
- U.S. Food and Drug Administration. FDA Issues Final Guidance on Prescription Drug Apps and Software. Published 2026-10-20. Read the source
Checked 23 October 2026. How we check sources